Acadian Asset Management
XERS icon

Acadian Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History

Acadian Asset Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Buy
+20,579
New +$131K ﹤0.01% 1671
2026
Q1 		– Sell
-971,598
Closed -$7.62M – 2276
2025
Q4 		$7.62M Buy
971,598
+50,495
+5% +$397K 0.01% 544
2025
Q3 		$7.5M Buy
921,103
+537,866
+140% +$3.57M 0.01% 538
2025
Q2 		$1.79M Buy
383,237
+365,641
+2,078% +$1.68M ﹤0.01% 859
2025
Q1 		$96K Buy
+17,596
New +$71K ﹤0.01% 1358

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AG
Algert Global San Francisco, California $8.43B AUM 80.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Acadian Asset Management's XERS Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Xeris Biopharma Holdings (XERS) in Q2 2026: 20,579 shares worth $162K. The stake represents ﹤0.01% of the portfolio and ranks #1671 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in XERS as recently as Q4 2025.

Acadian Asset Management first reported a position in XERS in Q1 2025 and has held it in 5 quarters since. The position peaked at $7.62M in Q4 2025. 163 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Acadian Asset Management held 20,579 shares of Xeris Biopharma Holdings worth $162K as of Q2 2026.
  • Xeris Biopharma Holdings was a new Acadian Asset Management position in Q2 2026.
  • Xeris Biopharma Holdings made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1671 holding.
  • Acadian Asset Management first reported a position in Xeris Biopharma Holdings in Q1 2025 and has held it in 5 quarters since.
  • Acadian Asset Management's Xeris Biopharma Holdings position peaked at $7.62M in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.